Blueprint Medicines Corp (NASDAQ: BPMC) is 4.75% higher on its value in year-to-date trading and has touched a low of $64.79 and a high of $121.90 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BPMC stock was last observed hovering at around $94.81 in the last trading session, with the day’s gains setting it 1.81%.
Currently trading at $96.62, the stock is 3.82% and 7.05% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.78 million and changing 1.91% at the moment leaves the stock 0.64% off its SMA200. BPMC registered 45.73% gain for a year compared to 6-month loss of -5.64%. The firm has a 50-day simple moving average (SMA 50) of $90.004 and a 200-day simple moving average (SMA200) of $95.89182.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 14.48% gain in the last 1 month and extending the period to 3 months gives it a 2.19%, and is 1.01% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.47% over the week and 4.39% over the month.
Blueprint Medicines Corp (BPMC) has around 655 employees, a market worth around $6.14B and $434.41M in sales. Profit margin for the company is -29.48%. Distance from 52-week low is 49.12% and -20.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-13.80%).
The EPS is expected to grow by 88.32% this year
453.0 institutions hold shares in Blueprint Medicines Corp (BPMC), with institutional investors hold 105.26% of the company’s shares. The shares outstanding are 63.53M, and float is at 62.34M with Short Float at 6.63%. Institutions hold 104.31% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 6.65 million shares valued at $716.45 million. The investor’s holdings represent 10.5758 of the BPMC Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 6.54 million shares valued at $704.72 million to account for 10.4026 of the shares outstanding. The other top investors are PRICE T ROWE ASSOCIATES INC /MD/ which holds 5.87 million shares representing 9.3445 and valued at over $633.03 million, while FMR LLC holds 7.6903 of the shares totaling 4.83 million with a market value of $520.97 million.
Blueprint Medicines Corp (BPMC) Insider Activity
Still, SEC filings show that on Nov 07 ’24, Albers Jeffrey W. (Director) disposed off 5,000 shares at an average price of $102.00 for $0.51 million. The insider now directly holds 157,557 shares of Blueprint Medicines Corp (BPMC).
